StockPulse is a software subscription service that translates and summarizes U.S. stock filings and news into alerts. It is not an investment advisory, brokerage, or discretionary management service.

All information provided (filing summaries, price data, keywords, etc.) is processed from public sources for reference only and is not a recommendation to buy or sell any security. Investment decisions and their outcomes are the sole responsibility of the user.

노마드랩 주식회사 · 대표 황승준 · 사업자등록번호 588-81-01342

부산광역시 해운대구 센텀중앙로 55, 9층 7호(우동)

통신판매업 제2026-부산해운대-0983호 · 문의  

고객문의 070-4268-1176

App Store▶ Google Play
GuideFAQWeeklyTerms of ServicePrivacy PolicyPayment & Refund Policy

StockPulse · 스탁펄스(스톡펄스) — 미국주식 공시·뉴스 실시간 알림

© 2026 노마드랩 주식회사. All rights reserved.

StockPulseStockPulseFeedReportMacro·SectorsCommunityAlertsMy
Theme
FeedReportMacro·SectorsCommunityAlertsMy
KNSAKiniksa Pharmaceuticals International, plc
stockpulse.co.kr
Nasdaq
$75.25▼ 1.88%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $5.79BShares out 76.9M sh
At a glance🔒 At-a-glance is MAX onlySee plans

Chart

Filings & news by date

Hover (PC) or tap (mobile) a candle to see that day only

🔒 Members only
Live tape🔒 Live tape is MAX onlySee plans

Filings

16
  • 2d agoAfter-hours26.10.23 05:28
    8-KKey event#●●●#●●●

    Kiniksa Pharmaceuticals International, plc

    Kiniksa Pharmaceuticals has appointed Ross Moat as President and Chief Operating Officer, effective immediately. Additionally, the company approved an increase in Mr. Moat's annual base salary to $700,000 and his annual target bonus to 60%, effective January 1, 2027.…more

    $75.25-1.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    View filingShare
  • 9.3After-hours26.09.04 05:49
    4Ownership

    Kiniksa Pharmaceuticals International, plc

    Kiniksa Pharmaceuticals insider Mark Ragosa filed a Form 4 report on September 3, 2026, regarding changes in beneficial ownership of securities as of September 1, 2026. This filing serves as an official disclosure of insider equity transactions to the SEC.…more

    $75.25-1.88%vs prev close
    View filingShare
  • 9.3After-hours26.09.04 05:48
    4Ownership

    Kiniksa Pharmaceuticals International, plc

    Director Sanj K. Patel of Kiniksa Pharmaceuticals reported a change in beneficial ownership of securities effective September 1, 2026. This filing is a standard Form 4 disclosure regarding insider stock holdings.…more

    $75.25-1.88%vs prev close
    View filingShare

15 more filings

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →

News

GlobeNewswire
  • 2d agoAfter-hours26.10.23 05:01
    #●●●#●●●

    Kiniksa Pharmaceuticals to Report Q3 2026 Financial Results

    Kiniksa Pharmaceuticals has scheduled its third quarter 2026 financial results announcement and conference call for October 27, 2026. This is a routine disclosure of an earnings event and is considered neutral for investors.…more

    $75.25-1.88%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
    Read sourceShareGlobeNewswire
  • 9.4After-hours26.09.05 05:01

    ●●●●●●●● ●●●●● ●●●●●●

    Kiniksa Pharmaceuticals will participate in a fireside chat at the upcoming 21st Annual Wells Fargo Healthcare Conference on September 9. The presentation will be available for viewing via a live webcast on the company's investor relations website.…more

    $75.25-1.88%vs prev close
    Read sourceShareGlobeNewswire
  • 8.7After-hours26.08.08 05:01

    ●●●●●●●● ●●●●● ●●●●●●

    키닉사 파마슈티컬스가 오는 8월 12일 카나코드 제뉴이티 연례 성장 컨퍼런스에서 경영진 대담을 진행합니다. 이번 행사를 통해 회사의 사업 전략과 파이프라인에 대한 최신 정보를 투자자들에게 공유할 예정입니다.…more

    $75.25-1.88%vs prev close
    Read sourceShareGlobeNewswire

2 more news items

Sign up free to unlock the full feed and real-time filing & news alerts.

  • ✓Free — no card required
  • ✓Full real-time filing & news feed
  • ✓Daily Today Report
Sign up free & see allPreview the Today Report →